Pharmaceuticals by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceuticals ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 16:02 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.3
- Combined market value
- NOK 49.33T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | NOK 43.4B | NOK 396.23 | 2.90% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.7 | NOK 199.3B | NOK 1,487.75 | 2.06% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | NOK 1.7T | NOK 385.94 | 2.31% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.3 | NOK 56.5B | NOK 83.04 | 0.87% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.3 | NOK 1.19T | NOK 581.92 | 2.28% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.3 | NOK 331B | NOK 814.74 | 0.55% up | 29% down | ||
| 7 | GSKGSK · Health Care | 17.0 | NOK 950.5B | NOK 474.17 | 0.79% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | NOK 172.2B | NOK 2,625.28 | 0.27% down | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.1 | NOK 960.4B | NOK 9,284.25 | 0.13% down | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.7 | NOK 237.2B | NOK 5,569.53 | 1.77% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.5 | NOK 1.1T | NOK 459.32 | 0.44% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.3 | NOK 2.69T | NOK 1,736.34 | 1.86% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.5 | NOK 79.3B | NOK 1,214.51 | 0.36% up | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.8 | NOK 2.87T | NOK 1,517.84 | 1.73% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.4 | NOK 1.32T | NOK 5,191.12 | 0.11% up | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.8 | NOK 1.75T | NOK 1,009.99 | 0.63% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.3 | NOK 1.56T | NOK 273.54 | 1.02% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.7 | NOK 121.4B | NOK 145.60 | 1.42% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.8 | NOK 6.43T | NOK 2,671.39 | 1.25% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 44.0 | NOK 307.9B | NOK 499.31 | 1.00% down | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.7 | NOK 382B | NOK 664.43 | 0.33% down | 78% up | ||
| 22 | Eli LillyLLY · Health Care | 45.0 | NOK 11.98T | NOK 13,450.53 | 2.11% down | 35% up | ||
| 23 | AbbVieABBV · Health Care | 49.6 | NOK 4.95T | NOK 2,799.76 | 1.50% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 51.7 | NOK 73B | NOK 666.90 | 1.95% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.9 | NOK 448.8B | NOK 3,929.29 | 2.05% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 54.1 | NOK 73.2B | NOK 210.01 | 2.44% up | 83% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 71.9 | NOK 151.4B | NOK 2,359.08 | 0.97% up | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.8 | NOK 73.3B | NOK 932.62 | 1.02% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 95.6 | NOK 94B | NOK 621.72 | 2.14% up | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.7 | NOK 480.9B | NOK 412.15 | 0.38% down | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 120 | NOK 58B | NOK 2,901.25 | 1.73% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 141 | NOK 3.34T | NOK 1,353.12 | 2.77% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 305 | NOK 662.6B | NOK 207.38 | 1.27% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7067 NOK). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceuticals have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.7) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceuticals ranked here as of 18 Nov 2026, 16:02 UTC.
How many pharmaceuticals are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 33 pharmaceuticals ranked by P/E ratio have a combined market value of NOK 49.33T as of 18 Nov 2026, 16:02 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceuticals by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.